Rufinamide
Banzel
NADAC/unit
$0.2629
No Shortage
Tier 1: 58.1%
PA Req: 164.4%
11 Manufacturers
23 ANDAs
1 I NDICATIONS AND USAGE BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults.
vs. brand Banzel: Generic saves up to 97% per unit
Market Intelligence
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2023-08-30 Class II Recall: Aurobindo Pharma USA Inc.
2023-08-30 Class II Recall: Aurobindo Pharma USA Inc.
Generic Manufacturers
ALKEM LABORATORIES LTDAUROBINDO PHARMA LTDBIONPHARMA INCCHARTWELL RX SCIENCES LLCEISAI INCGLENMARK PHARMACEUTICALS LTDHETERO LABS LTD UNIT IIIHIKMA PHARMACEUTICALS USA INCLUPIN LTDMICRO LABS LTDMSN LABORATORIES PRIVATE LTDPHARMOBEDIENT CONSULTING LLC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.